CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 57 enrolled
Drug / intervention
enzastaurindrug
Likely dose
enzastaurin 1125 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00542919
NCT00542919Phase 2Completed
CompareCT.gov

A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas

Eli Lilly and Company·interventional·Posted Oct 12, 2007·Updated Oct 19, 2020

In Brief

A Phase 2 clinical trial evaluating enzastaurin for T-Cell Lymphoma and B-Cell Lymphoma. Completed, enrolled 57 participants across 14 sites in 5 countries.

Detailed Summary

In this study, all patients will get investigational drug. There will be no comparator drug. This study will evaluate three tumor types: T-cell lymphoma, Indolent B-cell lymphoma, and Aggressive B-cell lymphoma. Each tumor type will include several tumor subtypes: * T-cell lymphoma: Peripheral and Cutaneous T-cell lymphoma (PTCL, CTCL) * Indolent B-cell lymphoma: Small lymphocytic lymphoma, follicular lymphoma (Gr 1 or 2) and marginal zone lymphoma * Aggressive B-cell lymphoma: Primary CNS lymphoma, follicular lymphoma (Gr 3a and 3b) and aggressive lymphoma with prior clinical history of indolent lymphoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsT-Cell Lymphoma, B-Cell Lymphoma
CountriesAustralia, Brazil, Mexico, Peru, United States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 12, 2007
Enrollment StartNov 1, 2007
Primary CompletionMar 1, 2010
Study CompletionFeb 27, 2018
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 18.7 years ago

Interventions

enzastaurindrug

1125 mg loading dose then 500 mg, oral, daily until progressive disease